IO Biotech (IOBT) Competitors

IO Biotech (NASDAQ:IOBT) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Do institutionals & insiders have more ownership in IOBT or ITOS?

54.8% of IO Biotech shares are owned by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are owned by institutional investors. 2.3% of IO Biotech shares are owned by company insiders. Comparatively, 12.5% of iTeos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Do analysts prefer IOBT or ITOS?

IO Biotech presently has a consensus target price of $9.33, suggesting a potential upside of 828.69%. iTeos Therapeutics has a consensus target price of $25.75, suggesting a potential upside of 351.75%. Given IO Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe IO Biotech is more favorable than iTeos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IO Biotech	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
iTeos Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, IOBT or ITOS?

IO Biotech has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Does the media refer more to IOBT or ITOS?

In the previous week, IO Biotech had 4 more articles in the media than iTeos Therapeutics. MarketBeat recorded 5 mentions for IO Biotech and 1 mentions for iTeos Therapeutics. IO Biotech's average media sentiment score of 0.51 beat iTeos Therapeutics' score of 0.00 indicating that IO Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IO Biotech	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iTeos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher earnings and valuation, IOBT or ITOS?

IO Biotech has higher earnings, but lower revenue than iTeos Therapeutics. iTeos Therapeutics is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IO Biotech	N/A	N/A	-$86.08M	-$1.37	-0.73
iTeos Therapeutics	$35M	6.22	-$112.64M	-$3.31	-1.72

Is IOBT or ITOS more profitable?

iTeos Therapeutics' return on equity of -20.11% beat IO Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IO Biotech	N/A	-86.56%	-75.24%
iTeos Therapeutics	N/A	-20.11%	-17.50%

Does the MarketBeat Community prefer IOBT or ITOS?

iTeos Therapeutics received 21 more outperform votes than IO Biotech when rated by MarketBeat users. However, 92.59% of users gave IO Biotech an outperform vote while only 80.70% of users gave iTeos Therapeutics an outperform vote.

Company	Underperform	Outperform
IO Biotech	Outperform Votes 25 92.59%	Underperform Votes 2 7.41%
iTeos Therapeutics	Outperform Votes 46 80.70%	Underperform Votes 11 19.30%

Summary

IO Biotech beats iTeos Therapeutics on 9 of the 17 factors compared between the two stocks.